Sec Form 13G Filing - ASTRAZENECA PLC filing for Viela Bio Inc. (VIE) - 2020-01-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

o

Rule 13d-1(b)

o

Rule 13d-1(c)

x

Rule 13d-1(d)

CUSIP No. 926613100

1.

Name of Reporting Person
AstraZeneca PLC

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

o

(b)

x (Joint filers)

3.

SEC Use Only

4.

Citizenship or Place of Organization
United Kingdom

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
14,650,334 shares(1)

6.

Shared Voting Power
0 shares

7.

Sole Dispositive Power
14,650,334 shares(2)

8.

Shared Dispositive Power
0 shares

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
14,650,334 shares(3)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

11.

Percent of Class Represented by Amount in Row (9)
28.7%(4)

12.

Type of Reporting Person (See Instructions)
CO

CUSIP No. 926613100

1.

Name of Reporting Person
AstraZeneca UK Limited

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

o

(b)

x (Joint filers)

3.

SEC Use Only

4.

Citizenship or Place of Organization
United Kingdom

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
14,650,334 shares(5)

6.

Shared Voting Power
0 shares

7.

Sole Dispositive Power
14,650,334 shares(6)

8.

Shared Dispositive Power
0 shares

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
14,650,334 shares(7)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

11.

Percent of Class Represented by Amount in Row (9)
28.7%(8)

12.

Type of Reporting Person (See Instructions)
CO

Item 1.

(a)

Name of Issuer
Viela Bio, Inc.

(b)

Address of Issuer’s Principal Executive Offices
One MedImmune Way, First Floor, Area Two

Gaithersburg, Maryland 20878

Item 2.

(a)

Name of Person Filing
See response to 2(c)

(b)

Address of Principal Business Office or, if none, Residence
See response to 2(c)

(c)

Citizenship
This statement is filed on behalf of:

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Citizenship: United Kingdom

AstraZeneca UK Limited

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Citizenship: United Kingdom

(d)

Title of Class of Securities
Common Stock, par value $0.001 per share

(e)

CUSIP Number
926613100

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

o

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

o

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

o

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

o

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

o

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)

o

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)

o

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)

o

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

o

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

o

A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);

(k)

o

Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with

§ 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)

Amount beneficially owned:   

14,650,334 shares

(b)

Percent of class:   

28.7%. The percentage stated herein is based on 50,962,060 share s of the issuer’s common stock outstanding as of November 14 2019, as reported in the Form 10-Q filed with the SEC on November 14, 2019.

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote:   

AstraZeneca PLC: 14,650,334 shares

AstraZeneca UK Limited: 14,650,334 shares

(ii)

Shared power to vote or to direct the vote:    

AstraZeneca PLC: 0 shares

AstraZeneca UK Limited: 0 shares

(iii)

Sole power to dispose or to direct the disposition of:   

AstraZeneca PLC: 14,650,334 shares

AstraZeneca UK Limited: 14,650,334 shares

(iv)

Shared power to dispose or to direct the disposition of:   

AstraZeneca PLC: 0 shares

AstraZeneca UK Limited: 0 shares

AstraZeneca UK Limited, a wholly owned subsidiary of AstraZeneca PLC, is the direct record holder of all 14,650,334 shares reported herein. Each of AstraZeneca UK Limited and AstraZeneca PLC may be deemed to have sole voting and dispositive power with respect to such shares.  

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.   o

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Not applicable.

Item 9.

Notice of Dissolution of Group

Not applicable.

Item 10.

Certifications

Not applicable.

AstraZeneca PLC

/s/ Adrian Kemp

Signature

Adrian Kemp, Company Secretary

Name/Title

AstraZeneca UK Limited

/s/ Adrian Kemp

Signature

Adrian Kemp, Company Secretary

Name/Title

ATTENTION:

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).